Table 1

Major recent or ongoing clinical trials using EULAR Sjögren’s Syndrome Disease Activity Index as their primary endpoint

NCT or EudraCT no.	Treatment and mode of action	Phase	Status	Patients (n)	Time of evaluation of primary endpoint	Results	Reference
NCT01782235	Tocilizumab	III	Completed	110	Week 24	Negative	2
NCT02067910	Abatacept	III	Completed	80	Week 24	Negative	7
NCT02915159	Abatacept	III	Completed	187	Day 169	Negative	8
NCT02962895	Ianalumab anti-BAFFR	IIb	Active, not recruiting	195	Week 24	Positive	5
NCT02291029	Iscalimab anti-CD40	II	Completed	44	Week 12	Positive	4
NCT03905525	Iscalimab anti-CD40	II	Recruiting	260	Week 24	Not yet reported
2014-003140-12	Leflunomide+hydroxychloroquine	IIa	Completed	29	Week 24	Positive	3
NCT02334306	Prezalumab anti-ICOSL	IIa	Terminated	32	Day 99	Negative	Not published
NCT02464319	Low dose IL-2	II	Completed	60	Week 24	Not yet reported
NCT02701985	Petesicatib cathepsine-S inhibitor	II	Completed	75	Week 12	Negative	Not published
NCT02775916	Leniolisib PI3Kδ inhibitor	II	Completed	30	Week 12	Negative	Not published
NCT03100942	Filgotinib anti-JAK1 Lanraplenib SYK inhibitor Tirabrutinib BTK inhibitor	II	Completed	152	Week 12	Negative	Not published
NCT04035668	LOU064 BTK inhibitor	II	Recruiting	252	Week 24	Not yet reported
NCT04078386	RC18 TACI fusion protein	II	Recruiting	30	Week 24	Not yet reported
NCT02610543	Seletalisib PI3Kδ inhibitor	II	Terminated (enrolment challenges)	27	Week 12	Negative	9
NCT02843659	Lulizumab anti-CD28, BMS-986142 BTK inhibitor	II	Terminated	45	Week 24	Not yet reported
NCT03023592	Iguratimod	I/II	Recruiting	30	Week 24	Not yet reported

Eudra-CT, European Union Drug Regulating Authorities Clinical Trials; IL, interleukin; NCT, ClinicalTrials.gov Identifier.